CSIMarket
 


Quidelortho Corp  (QDEL)
Other Ticker:  
 
 

QDEL's Revenue Growth by Quarter and Year

Quidelortho's Revenue results by quarter and year




QDEL Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
IV Quarter December - 744.00 783.80 509.74
III Quarter September - 665.10 613.40 176.61
II Quarter June - 846.10 1,002.26 375.34
I Quarter March 711.00 866.54 636.87 809.20
FY   711.00 3,121.74 3,036.33 1,870.89



QDEL Revenue first quarter 2024 Y/Y Growth Comment
Quidelortho Corp reported decline in Revenue in the first quarter 2024 by -17.95% to $ 711.00 millions, from the same quarter in 2023.
The contraction in the first quarter 2024 Quidelortho Corp's Revenue compares unfavorably to the Company's average Revenue jump of 42.39%.

Looking into first quarter 2024 results within In Vitro & In Vivo Diagnostic Substances industry 3 other companies have achieved higher Revenue growth. While Quidelortho Corp' s Revenue fall of -17.95% ranks overall at the positon no. 765 in the first quarter 2024.




QDEL Revenue ( Y/Y Growth %) 2024
2023 2022 2021
IV Quarter December - -5.08 % 53.76 % 7.07 %
III Quarter September - 8.43 % 247.32 % -12.46 %
II Quarter June - -15.58 % 167.03 % 114.91 %
I Quarter March -17.95 % 36.06 % -21.3 % 431.74 %
FY   - 2.81 % 62.29 % 86.22 %

Financial Statements
Quidelortho's first quarter 2024 Revenue $ 711.00 millions QDEL's Income Statement
Quidelortho's first quarter 2023 Revenue $ 866.54 millions Quarterly QDEL's Income Statement
New: More QDEL's historic Revenue Growth >>


QDEL Revenue (Quarter on Quarter Growth %)

2024
2023 2022 2021
IV Quarter December - 11.86 % 27.78 % 188.62 %
III Quarter September - -21.39 % -38.8 % -52.95 %
II Quarter June - -2.36 % 57.37 % -53.62 %
I Quarter March -4.44 % 10.56 % 24.94 % 69.98 %
FY (Year on Year)   - 2.81 % 62.29 % 86.22 %




Revenue first quarter 2024 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #4
Healthcare Sector #149
Overall #765

Revenue Y/Y Growth Statistics
High Average Low
231.63 % 42.39 % -11.79 %
(Mar 31 2021)   (June 30. 2014)
Revenue first quarter 2024 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #4
Healthcare Sector #149
Overall #765
Revenue Y/Y Growth Statistics
High Average Low
231.63 % 42.39 % -11.79 %
(Mar 31 2021)   (June 30. 2014)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Quidelortho's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
188.62 % 17.29 % -53.62 %
(Sep 30 2021)  


QDEL's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2024 Quidelortho Corp disclosed fall in Revenue from the previous quarter by -4.44% to $ 711.00 millions, from $ 744.00 millions achived a quarter before.

Those cyclical factors have not rescue the I. Quarter for the Quidelortho Corp, Steph Pinto, Healthcare sector veteran from Madrid wrote, she voiced certan skepticism conserning QDEL's direction, she sees additional challenges onward for QDEL.

Within In Vitro & In Vivo Diagnostic Substances industry 2 other companies have achieved higher Revenue quarter on quarter growth. While Quidelortho's Revenue growth quarter on quarter, overall rank is 1278.


Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #3
Healthcare Sector #155
Overall #1278
Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #3
Healthcare Sector #155
Overall #1278
Revenue Q/Q Growth Statistics
High Average Low
188.62 % 17.29 % -53.62 %
(Sep 30 2021)  


QDEL's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2024 Quidelortho Corp disclosed fall in Revenue sequentially by -4.44% to $ 711.00 millions, from $ 744.00 millions achived in the previous reporting period.

Albeit periodic factors commonly elevate I. Quarter 2024 results, this simply was not sufficient to rescue In Vitro & In Vivo Diagnostic Substances's company I. Quarter 2024 performance, Steph Pinto, Healthcare sector veteran from Madrid wrote.

Within In Vitro & In Vivo Diagnostic Substances industry 2 other companies have achieved higher Revenue quarter on quarter growth. While Quidelortho's Revenue growth quarter on quarter, overall rank is 1278.


Quidelortho's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2024)
12 Months Ending
(Oct 01 2023)
12 Months Ending
(Jul 02 2023)
12 Months Ending
(Apr 02 2023)
12 Months Ending
(Jan 01 2023)
Cumulative Revenue 12 Months Ending $ 2,966.20 $ 3,121.74 $ 3,161.54 $ 3,109.84 $ 3,266.00
Y / Y Revenue Growth (TTM) -9.18 % 2.81 % 14.45 % 33.73 % 92.28 %
Year on Year Revenue Growth Overall Ranking # 43 # 54 # 734 # 1139 # 165
Seqeuential Revenue Change (TTM) -4.98 % -1.26 % 1.66 % -4.78 % 7.56 %
Seq. Revenue Growth (TTM) Overall Ranking # 765 # 421 # 456 # 693 # 1984




Cumulative Revenue growth Comment
For the 12 months ended Mar 31 2024 Quidelortho reported a decrease in Revenue by -9.18% year on year, to $2,966 millions, compare to the 2.81% growth at Oct 01 2023.

Among companies within the Healthcare sector 15 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 43, from total ranking in previous quarter at 54.

Revenue TTM Q/Q Growth Statistics
High Average Low
231.63 %
42.39 %
-11.79 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 4
Healthcare Sector # 16
Overall # 43

Revenue TTM Y/Y Growth Statistics
High Average Low
231.63 %
42.39 %
-11.79 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 4
Sector # 149
S&P 500 # 765
Cumulative Revenue growth Comment
For the 12 months ended Mar 31 2024 Quidelortho reported a decrease in Revenue by -9.18% year on year, to $2,966 millions, compare to the 2.81% growth at Oct 01 2023.

Among companies within the Healthcare sector 15 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 43, from total ranking in previous quarter at 54.

Revenue TTM Q/Q Growth Statistics
High Average Low
231.63 %
42.39 %
-11.79 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 4
Healthcare Sector # 16
Overall # 43

Revenue TTM Y/Y Growth Statistics
High Average Low
231.63 %
42.39 %
-11.79 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 4
Sector # 149
S&P 500 # 765




Other Revenue Growth
In Vitro & In Vivo Diagnostic Substances Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
QDEL's Revenue Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for QDEL's Competitors
Revenue Growth for Quidelortho's Suppliers
Revenue Growth for QDEL's Customers

You may also want to know
QDEL's Annual Growth Rates QDEL's Profitability Ratios QDEL's Asset Turnover Ratio QDEL's Dividend Growth
QDEL's Roe QDEL's Valuation Ratios QDEL's Financial Strength Ratios QDEL's Dividend Payout Ratio
QDEL's Roa QDEL's Inventory Turnover Ratio QDEL's Growth Rates QDEL's Dividend Comparisons



Companies with similar Revenue decrease for the quarter ending Mar 31 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2024
Collegium Pharmaceutical inc -0.21%$ -0.215 millions
Mettler Toledo International Inc-0.30%$ -0.300 millions
3m Company-0.35%$ -0.349 millions
Icu Medical Inc-0.42%$ -0.423 millions
Lifeloc Technologies Inc -0.51%$ -0.513 millions
Regeneron Pharmaceuticals Inc -0.54%$ -0.541 millions
Envista Holdings Corporation-0.62%$ -0.622 millions
Vyne Therapeutics Inc -1.01%$ -1.010 millions
Ge Healthcare Technologies Inc -1.50%$ -1.502 millions
Baxter International Inc -1.56%$ -1.562 millions
Y mabs Therapeutics inc -1.58%$ -1.580 millions
Pacific Biosciences Of California Inc -1.59%$ -1.589 millions
Cartesian Therapeutics Inc -1.65%$ -1.650 millions
Viatris Inc -1.76%$ -1.762 millions
Ocuphire Pharma Inc -2.17%$ -2.173 millions
Vaso Corporation-2.51%$ -2.513 millions
Dentsply Sirona Inc -2.56%$ -2.556 millions
Alpha Pro Tech Ltd -2.78%$ -2.775 millions
Prestige Consumer Healthcare Inc -2.82%$ -2.817 millions
West Pharmaceutical Services Inc -2.99%$ -2.986 millions
Integra Lifesciences Holdings Corp-3.14%$ -3.144 millions
Accelerate Diagnostics Inc -3.17%$ -3.165 millions
National Research Corporation-3.18%$ -3.180 millions
Catheter Precision Inc -3.53%$ -3.529 millions
Elanco Animal Health Inc-4.14%$ -4.137 millions
Ptc Therapeutics inc -4.66%$ -4.657 millions
Foghorn Therapeutics Inc -4.88%$ -4.879 millions
Aclaris Therapeutics Inc -5.14%$ -5.142 millions
Avantor Inc -5.65%$ -5.645 millions
The Beauty Health Company-5.70%$ -5.699 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com